Literature DB >> 17243926

Validation of an automated sensitive immunoassay for quantitation of cytokines in the sputum of cystic fibrosis patients.

Amedea Silvia Tirelli1, Carla Colombo, Erminio Torresani, Lisa Cariani, Enrico Arnaboldi, Massimo Conese.   

Abstract

BACKGROUND: There is little information on the reproducibility of measurement of cytokine levels in sputum obtained from cystic fibrosis (CF) patients. Our aim was to investigate whether assay of cytokine levels in CF sputum is reproducible or is hampered by proteolytic degradation.
METHODS: Interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-alpha) levels were measured in native and spiked samples (fresh or after freezing for 15 and 23 days at -70 degrees C) obtained from nine CF patients using an immunometric assay with chemiluminescent substrate run on a IMMULITE analyzer.
RESULTS: For both cytokines, linearity was >0.98 for dilutions up to 1:32. After storage, cytokine concentrations in native samples varied between -2.9% and -5.6% for IL-8 and between 0.4% and 3.0% for TNF-alpha. In spiked samples, concentrations increased by 5.8%-12.6% for TNF-alpha and decreased by 3.8%-14.3% for IL-8 after 15 and 23 days of storage. In samples spiked with cytokines, the mean recovery rates for IL-8 and TNF-alpha were 109.4% and 106.3%, respectively.
CONCLUSIONS: Measurement of IL-8 and TNF-alpha in CF sputum is reproducible and is not hampered by freezing and thawing of samples.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17243926     DOI: 10.1515/CCLM.2007.019

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  5 in total

1.  Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.

Authors:  J Kirk Harris; Brandie D Wagner; Edith T Zemanick; Charles E Robertson; Mark J Stevens; Sonya L Heltshe; Steven M Rowe; Scott D Sagel
Journal:  Ann Am Thorac Soc       Date:  2020-02

Review 2.  Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Authors:  Scott D Sagel; James F Chmiel; Michael W Konstan
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

Review 3.  Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.

Authors:  Geraint B Rogers; Lucas R Hoffman; Matt W Johnson; Nicole Mayer-Hamblett; Jürgen Schwarze; Mary P Carroll; Kenneth D Bruce
Journal:  Expert Rev Mol Diagn       Date:  2011-03       Impact factor: 5.225

4.  Validation of Sputum Biomarker Immunoassays and Cytokine Expression Profiles in COPD.

Authors:  Alex Mulvanny; Caroline Pattwell; Augusta Beech; Thomas Southworth; Dave Singh
Journal:  Biomedicines       Date:  2022-08-11

5.  Evaluation of airway and circulating inflammatory biomarkers for cystic fibrosis drug development.

Authors:  Raksha Jain; Arthur Baines; Umer Khan; Brandie D Wagner; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2020-07-01       Impact factor: 5.482

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.